OKYO · OKYO Pharma Limited

Summary

OKYO Pharma Limited announced that Gary Jacob, Chief Development Officer and Director, acquired 30,980 ordinary shares on NASDAQ at $1.59, increasing his total holding to 108,920 shares. The company develops Urcosimod for neuropathic corneal pain and inflammatory eye diseases, with recent positive Phase 2a trial data and plans for a ~150-subject Phase 2b/3 study in the first half of 2026.

Key takeaways

• Gary Jacob, Chief Development Officer and Director, acquired 30,980 ordinary shares at $1.59 on NASDAQ
• Gary Jacob's total holding increased to 108,920 ordinary shares
• Positive pain reduction data from Phase 2a trial in 18 neuropathic corneal pain subjects
• Earlier Phase 2 trial of Urcosimod in 240 dry eye disease subjects
• Plans to initiate ~150-subject Phase 2b/3 multiple-dose study of Urcosimod for NCP in first half of 2026